Phase 3 N=98 A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Bullous Pemphigoid
Primary: Number of Participants With CRoff at Week 36 — 8; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=84 Immersive Virtual Reality Exposure for Reducing Preoperative Anxiety in Children
Anxiety State · Satisfaction · Compliance
Primary: Modified Yale Preoperative Anxiety Scale (mYPAS) (T1) — 31.4; 37.3 score on a scale
Phase 2 N=34 Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients
Hypertension
Primary: Categorical Classification of Subjects Into Responders vs. Non-responders — 10; 2; 4; 19 Participants
Phase 2 N=100 Evolocumab in Patients With Acute MI
Acute Coronary Syndrome
Primary: Change in LDL-Cholesterol — -70.59; -44.78 percent change mg/dL — p=.0001
N/A N=72 Emla-Cream as Pain Relief During Pneumococcal Vaccination
Children · Pain
Primary: Measuring the Effect of Emla Cream on Pain Perception During Pneumococcal Vaccination Measured With Five Items; Face, Legs, Activity, Cry, Consolability (FLACC Scale)…
Phase 2 N=15 Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia
Oral Cavity Carcinoma · Oral Intraepithelial Neoplasia
Primary: Oral Cancer-free Survival — NA; 6.7 Months
Phase 4 N=360 EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Chronic Rhinosinusitis With Nasal Polyps · Asthma
Primary: Change From Baseline to Week 24 in Nasal Polyp Score — -2.65; -1.05 score on a scale — p=<0.001
N/A N=24 Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Trial
Obesity
Primary: Durability — 1.2; 3.0; 1.4; 3.0 Score on a scale — p=<0.01
N/A N=196 Implementing and Sustaining a Sleep Treatment to Improve Community Mental Health Part 2: Train-the-Trainer
Sleep Disorder · Circadian Dysregulation
Primary: Patient-level Outcome: Patient-Reported Outcomes Measurement Information System - Sleep DisturbanceMeasurement Information System - Sleep Disturbance — 66.67; 62.21…
Phase 2 N=25 Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
B-Cell Non-Hodgkin Lymphoma
Primary: Absence of Any Grade Cytokine Release Syndrome (CRS) — 16; 9 Participants
Phase 2 N=11 First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
Pompe Disease
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Adverse Events (AEs) Leading to Discontinuation of Study…
Phase 2 N=686 A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
SARS-CoV-2 · COVID-19
Primary: Part A: Geometric Mean Titer (GMT) of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XX Spike Protein — 1266.7; 1786.9; 2122.1; 2218.6 Titers
Phase 2 N=6 Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH
Post-Traumatic Headache
Primary: Change in the Number of Days Experiencing Moderate-to-Severe Headaches — -8; -0.33 Days
Phase 2 N=79 Traditional Chinese Medicine (TCM) for Temporomandibular Dysfunction (TMD): A Whole Systems Multi-site Trial
Temporomandibular Dysfunction
Primary: Characteristic Facial Pain Score — 6.52; 6.55; 5.11; 5.47 units on a scale — p=0.020
N/A N=30 Efficacy of Photobiomodulation Therapy Using 980nm Versus 635nm Diode Lasers for Treatment of Myofascial Pain
Myofascial Pain Syndrome
Primary: Pain Intensity Reduction — 7.6; 7.8; 3.2; 2.5 "units on scale — p=0.05